Marrow sets out to challenge genetic medicines for severe blood diseases
Armed with $173 million in venture funding, the startup is developing what it’s positioning as a more accessible alternative to gene therapy and gene editing treatments for sickle cell and beta thalassemia.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.